Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory‐approved, to treat medical conditions as prescribed therapeutic interventions. There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards. DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions.
This report provides an overview of current marketed and pipeline DTx products within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China).
GlobalData’s Digital Therapeutics and Their Impact on Healthcare report combines primary research from a cross-specialty panel of experts with in-house analyst expertise to provide an assessment of the development landscape.
Components of the slide deck include primary and secondary research:
• Quotes from 10 key opinion leaders (7 US, 1 EU, 2 Japan) and 2 payers (1 US and 1 UK)
• Summary of DTx product definitions and classifications
• Overview of key DTx marketed products and key pipeline DTx products
• Trends in DTx market
• Call-outs of key information and details
• Insight from GlobalData’s specialist healthcare analysts
Reasons to buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global DTx market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DTx market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Proteus Digital Health
Table of Contents
Table of Contents (PowerPoint Deck)
1.1 Table of Contents
1.3 Related Reports
2 Executive Summary
2.1 Key Findings
2.2 KOL and Payer Insight
3 Overview – Digital Therapeutics (DTx)
3.1 Digital Therapeutics Definition
3.2 Digital Medicine Definition
3.3 Key Criteria of Digital Therapeutics
3.4 Positioning DTx Within Digital Health
4 DTx Technologies
4.1 Use of Digital Therapeutics
4.2 Types of Digital Therapeutics
4.3 DTx in Clinical Trials
4.4 KOL Perspectives
5 DTx Marketed Products
5.1 Leading Marketed Products
5.2 Key Marketed Products
5.3 Marketed DTx by Device Type
5.4 Marketed DTx by Indication
6 DTx Pipeline Products
6.1 Leading Pipeline Products
6.2 Key Pipeline Products
6.3 Clinical Trial Mapping
6.4 Pipeline DTx by Device Type
6.5 Pipeline DTx by Indication
7 Digital Medicine
7.2 Marketed Digital Medicine
7.3 Proteus Discover Products
7.4 Clinical Trial Mapping
7.5 Pipeline Digital Medicine
8 DTx Impact on Healthcare
8.2 Role of DTx and Digital Medicine in Clinical Unmet Needs
8.3 KOL Perspectives
8.4 Patient Perspective
8.5 Provider Perspective
8.6 Payer Perspective
8.7 Health System
8.8 What Do Physicians Think?
9 Trends in Digital Therapeutics
9.2 Clinical Trial Design
9.3 Regulatory Approvals
9.4 Opportunities for Pharma Companies
9.5 Deals Landscape
9.5 KOLs Perspectives
9.5 Case Studies
10 Market Opportunities
10.2 Market Drivers
10.3 Market Barriers
10.4 What Do Physicians Think?
11 DTx Market Access
11.1 Regulatory and Approval in US and EU
11.2 Regulatory and Approval in Japan and China
11.3 Developing a Market Access Strategy for DTx
11.4 What Do Payers Think?
11.5 DTx Regulation in US
11.6 DTx Reimbursement in US
11.6.1 What Do US Payers Think?
11.7 DTx Regulation in UK
11.7.1 DTx Reimbursement in UK
11.8 What Do UK Payers Think?
12 Market Outlook
12.2 Future Directions for DTx
13.3 Primary Research
13.4 About the Authors
13.5 About GlobalData
13.6 Contact Us